Belmont, CA, United States of America

Megha Vaman Rao

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Innovator Spotlight: Megha Vaman Rao**

Introduction

Megha Vaman Rao is a notable inventor based in Belmont, California. She has made significant contributions to the field of immunology through her innovative work in developing antibodies that modulate immune responses. With a keen focus on therapeutic applications, her inventions aim to address critical health challenges, including cancer and autoimmune diseases.

Latest Patents

Megha holds a patent for "BTLA-binding antibodies for modulating immune response and treating disease." This invention presents novel anti-BTLA antibodies and pharmaceutical compositions that leverage these antibodies for treating various diseases. The patent underscores her expertise in creating therapeutic methods that can profoundly impact patient care and treatment options for complex health conditions.

Career Highlights

Throughout her career, Megha Vaman Rao has worked with prominent companies in the biotechnology sector. She has been associated with Curia IP Holdings, LLC, a firm known for its commitment to developing innovative solutions in the life sciences arena. Additionally, she has collaborated with Trianni, Inc., a company focused on improving antibody discovery processes. Her experiences in these organizations have honed her skills as an inventor and researcher.

Collaborations

In her journey as an inventor, Megha has collaborated with esteemed professionals, including Brian A Zabel and John A Lippincott. These partnerships exemplify the collaborative spirit often found in innovative environments where diverse expertise merges to drive groundbreaking advancements.

Conclusion

Megha Vaman Rao is a remarkable inventor whose work in antibody development holds promise for transformative treatments in immunology. With her innovative approach and significant collaborations, she continues to pave the way for advancements that could potentially change the landscape of disease management and therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…